🚀 VC round data is live in beta, check it out!
BridgeBio Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for BridgeBio Pharma and similar public comparables like Ascendis Pharma, Torrent Pharmaceuticals, Yunnan Baiyao Group, Kelun-Biotech and more.
BridgeBio Pharma Overview
About BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Founded
2019
HQ
Employees
839
Website
Sectors
Financials (LTM)
EV
$16B
BridgeBio Pharma Financials
BridgeBio Pharma reported last 12-month revenue of $625M and negative EBITDA of ($441M).
In the same LTM period, BridgeBio Pharma generated $595M in gross profit, ($441M) in EBITDA losses, and had net loss of ($627M).
Revenue (LTM)
BridgeBio Pharma P&L
In the most recent fiscal year, BridgeBio Pharma reported revenue of $502M and EBITDA of ($520M).
BridgeBio Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $625M | XXX | $502M | XXX | XXX | XXX |
| Gross Profit | $595M | XXX | $481M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | ($441M) | XXX | ($520M) | XXX | XXX | XXX |
| EBITDA Margin | (71%) | XXX | (104%) | XXX | XXX | XXX |
| EBIT Margin | (72%) | XXX | (100%) | XXX | XXX | XXX |
| Net Profit | ($627M) | XXX | ($725M) | XXX | XXX | XXX |
| Net Margin | (100%) | XXX | (144%) | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BridgeBio Pharma Stock Performance
BridgeBio Pharma has current market cap of $15B, and enterprise value of $16B.
Market Cap Evolution
BridgeBio Pharma's stock price is $76.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16B | $15B | -0.9% | XXX | XXX | XXX | $-3.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBridgeBio Pharma Valuation Multiples
BridgeBio Pharma trades at 25.9x EV/Revenue multiple, and (36.6x) EV/EBITDA.
EV / Revenue (LTM)
BridgeBio Pharma Financial Valuation Multiples
As of April 19, 2026, BridgeBio Pharma has market cap of $15B and EV of $16B.
Equity research analysts estimate BridgeBio Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BridgeBio Pharma has a P/E ratio of (23.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15B | XXX | $15B | XXX | XXX | XXX |
| EV (current) | $16B | XXX | $16B | XXX | XXX | XXX |
| EV/Revenue | 25.9x | XXX | 32.2x | XXX | XXX | XXX |
| EV/EBITDA | (36.6x) | XXX | (31.1x) | XXX | XXX | XXX |
| EV/EBIT | (35.9x) | XXX | (32.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 27.1x | XXX | 33.6x | XXX | XXX | XXX |
| P/E | (23.7x) | XXX | (20.5x) | XXX | XXX | XXX |
| EV/FCF | (61.0x) | XXX | (57.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BridgeBio Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BridgeBio Pharma Margins & Growth Rates
BridgeBio Pharma's revenue in the last 12 month grew by 78%.
BridgeBio Pharma's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.2M for the same period.
BridgeBio Pharma's rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BridgeBio Pharma's rule of X is 178% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BridgeBio Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 78% | XXX | 82% | XXX | XXX | XXX |
| EBITDA Margin | (71%) | XXX | (104%) | XXX | XXX | XXX |
| EBITDA Growth | (84%) | XXX | (51%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 178% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 93% | XXX | 106% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 74% | XXX | 90% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 196% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BridgeBio Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BridgeBio Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascendis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Torrent Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Yunnan Baiyao Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Kelun-Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Regencell Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BridgeBio Pharma M&A Activity
BridgeBio Pharma acquired XXX companies to date.
Last acquisition by BridgeBio Pharma was on XXXXXXXX, XXXXX. BridgeBio Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BridgeBio Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBridgeBio Pharma Investment Activity
BridgeBio Pharma invested in XXX companies to date.
BridgeBio Pharma made its latest investment on XXXXXXXX, XXXXX. BridgeBio Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BridgeBio Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BridgeBio Pharma
| When was BridgeBio Pharma founded? | BridgeBio Pharma was founded in 2019. |
| Where is BridgeBio Pharma headquartered? | BridgeBio Pharma is headquartered in United States. |
| How many employees does BridgeBio Pharma have? | As of today, BridgeBio Pharma has over 839 employees. |
| Who is the CEO of BridgeBio Pharma? | BridgeBio Pharma's CEO is Neil Kumar. |
| Is BridgeBio Pharma publicly listed? | Yes, BridgeBio Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of BridgeBio Pharma? | BridgeBio Pharma trades under BBIO ticker. |
| When did BridgeBio Pharma go public? | BridgeBio Pharma went public in 2019. |
| Who are competitors of BridgeBio Pharma? | BridgeBio Pharma main competitors are Ascendis Pharma, Torrent Pharmaceuticals, Yunnan Baiyao Group, Kelun-Biotech. |
| What is the current market cap of BridgeBio Pharma? | BridgeBio Pharma's current market cap is $15B. |
| What is the current revenue of BridgeBio Pharma? | BridgeBio Pharma's last 12 months revenue is $625M. |
| What is the current revenue growth of BridgeBio Pharma? | BridgeBio Pharma revenue growth (NTM/LTM) is 78%. |
| What is the current EV/Revenue multiple of BridgeBio Pharma? | Current revenue multiple of BridgeBio Pharma is 25.9x. |
| Is BridgeBio Pharma profitable? | No, BridgeBio Pharma is not profitable. |
| What is the current EBITDA of BridgeBio Pharma? | BridgeBio Pharma has negative EBITDA and is not profitable. |
| What is BridgeBio Pharma's EBITDA margin? | BridgeBio Pharma's last 12 months EBITDA margin is (71%). |
| What is the current EV/EBITDA multiple of BridgeBio Pharma? | Current EBITDA multiple of BridgeBio Pharma is (36.6x). |
| What is the current FCF of BridgeBio Pharma? | BridgeBio Pharma's last 12 months FCF is ($265M). |
| What is BridgeBio Pharma's FCF margin? | BridgeBio Pharma's last 12 months FCF margin is (42%). |
| What is the current EV/FCF multiple of BridgeBio Pharma? | Current FCF multiple of BridgeBio Pharma is (61.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.